Aquestive Therapeutics Inc
AQST3.950USD
+0.130+3.40%
Market hours （ET）Quotes delayed by 15 min
392.30MMarket Cap
LossP/E TTM
More Details of Aquestive Therapeutics Inc Company
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
Company Info
Ticker SymbolAQST
Company nameAquestive Therapeutics Inc
IPO dateJul 25, 2018
CEOMr. Daniel Barber
Number of employees142
Security typeOrdinary Share
Fiscal year-endJul 25
Address30 Technology Dr
CityWARREN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code07059-5166
Phone19089411900
Websitehttps://aquestive.com/
Ticker SymbolAQST
IPO dateJul 25, 2018
CEOMr. Daniel Barber
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel Barber
Mr. Daniel Barber
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.85M
+33.44%
Ms. Lori J. Braender, J.D.
Ms. Lori J. Braender, J.D.
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
649.24K
+36.11%
Dr. Carl N. Kraus, M.D.
Dr. Carl N. Kraus, M.D.
Chief Medical Officer
Chief Medical Officer
313.57K
+24.59%
Mr. Peter E. Boyd
Mr. Peter E. Boyd
Senior Vice President - Information Technology, Human Resources and Communications
Senior Vice President - Information Technology, Human Resources and Communications
303.11K
+27.67%
Ms. Cassie Jung
Ms. Cassie Jung
Chief Operating Officer
Chief Operating Officer
293.84K
+26.99%
Ms. Sherry Korczynski
Ms. Sherry Korczynski
Chief Commercial Officer
Chief Commercial Officer
156.86K
-1.70%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
75.08K
--
Dr. Marco Taglietti, M.D.
Dr. Marco Taglietti, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy E. Morris, CPA
Mr. Timothy E. Morris, CPA
Independent Director
Independent Director
--
--
Ms. Stephanie Carrington
Ms. Stephanie Carrington
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel Barber
Mr. Daniel Barber
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.85M
+33.44%
Ms. Lori J. Braender, J.D.
Ms. Lori J. Braender, J.D.
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
649.24K
+36.11%
Dr. Carl N. Kraus, M.D.
Dr. Carl N. Kraus, M.D.
Chief Medical Officer
Chief Medical Officer
313.57K
+24.59%
Mr. Peter E. Boyd
Mr. Peter E. Boyd
Senior Vice President - Information Technology, Human Resources and Communications
Senior Vice President - Information Technology, Human Resources and Communications
303.11K
+27.67%
Ms. Cassie Jung
Ms. Cassie Jung
Chief Operating Officer
Chief Operating Officer
293.84K
+26.99%
Ms. Sherry Korczynski
Ms. Sherry Korczynski
Chief Commercial Officer
Chief Commercial Officer
156.86K
-1.70%
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
United States
5.20M
0.00%
Ex-United States
3.52M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 23
Updated: Fri, May 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Crestline Investors, Inc.
9.88%
BlackRock Institutional Trust Company, N.A.
5.48%
The Vanguard Group, Inc.
4.10%
Perceptive Advisors LLC
3.75%
Armistice Capital LLC
2.77%
Other
74.02%
Shareholders
Shareholders
Proportion
Crestline Investors, Inc.
9.88%
BlackRock Institutional Trust Company, N.A.
5.48%
The Vanguard Group, Inc.
4.10%
Perceptive Advisors LLC
3.75%
Armistice Capital LLC
2.77%
Other
74.02%
Shareholder Types
Shareholders
Proportion
Investment Advisor
16.61%
Hedge Fund
16.46%
Individual Investor
6.00%
Investment Advisor/Hedge Fund
5.80%
Private Equity
5.10%
Research Firm
4.75%
Bank and Trust
0.10%
Venture Capital
0.08%
Pension Fund
0.02%
Other
45.09%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
267
54.56M
54.93%
-2.83M
2025Q1
270
54.42M
54.80%
-3.81M
2024Q4
246
52.68M
57.78%
-5.60M
2024Q3
235
56.04M
61.46%
+1.93M
2024Q2
197
48.34M
53.08%
-1.69M
2024Q1
166
46.95M
51.85%
+18.59M
2023Q4
129
27.01M
40.12%
+751.99K
2023Q3
131
26.75M
41.08%
+3.52M
2023Q2
143
22.79M
40.65%
+3.05M
2023Q1
161
18.71M
33.39%
-2.52M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Crestline Investors, Inc.
9.81M
9.88%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.44M
5.48%
-78.94K
-1.43%
Mar 31, 2025
The Vanguard Group, Inc.
4.07M
4.1%
-273.20K
-6.29%
Mar 31, 2025
Perceptive Advisors LLC
3.73M
3.75%
+3.73M
--
Mar 31, 2025
Armistice Capital LLC
2.75M
2.77%
+2.75M
--
Sep 30, 2024
Barber (Daniel)
1.85M
1.86%
+462.91K
+33.44%
Mar 21, 2025
Geode Capital Management, L.L.C.
1.70M
1.71%
+46.11K
+2.79%
Mar 31, 2025
State Street Global Advisors (US)
1.52M
1.53%
+18.76K
+1.25%
Mar 31, 2025
Pale Fire Capital SE
1.34M
1.34%
+809.93K
+154.05%
Mar 31, 2025
BofA Global Research (US)
1.33M
1.34%
+640.24K
+92.75%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.55%
iShares Micro-Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.55%
iShares Micro-Cap ETF
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
